Answers are grounded in this paper and cite their sources.
Serum uric acid (SUA) and renal status are associated with the Cardiovascular-Kidney-Metabolic (CKM) syndrome. However, the causal association among them along with drug therapy need to be explored. We employed univariable, multivariate, mediation and drug-target mendelian randomization. Inverse variance weighting was the primary result, with extensive sensitivity analyses conducted to ensure robustness and reliability. Regarding SUA, genetically predicted SUA demonstrated a potential risk effect on stage 4 of CKM syndrome (ischemic heart disease (IHD), OR = 1.090, 95 %CI: 1.003–1.184; peripheral artery disease, OR = 1.174, 95 %CI: 1.058–1.303). SUA remained a significant risk factor after excluding the confounding of eGFR and proteinuria (IHD: OR = 1.137, 95 %CI: 1.043–1.238; peripheral artery disease: OR = 1.224, 95 %CI: 1.107–1.354). SUA mediated the following causal effect: sleep apnea (2.37 %), income (1.92 %) and education (1.79 %) on IHD; C-reactive protein (11.65 %) and education (4.29 %) on peripheral artery disease. Regarding renal status, renal dysfunction led to a wider phenotype of CKM syndrome including hypertension, cerebrovascular disease, chronic kidney disease and renal failure. Similarly, renal status mediated the causal effect of education on hypertension (1.84 %), depression on cerebrovascular (0.46 %) and family history of diabetes on chronic kidney disease (3.49 %) and renal failure (2.81 %). Lesinurad targeting SLC22A11 and SLC22A12 was validated for treating IHD. Our study clarified the complex relationship among SUA, renal status and CKM syndrome. Simultaneously providing innovative drug and social interventions for CKM syndrome. Lay summaries We identified elevated serum uric acid (SUA) is the culprit behind ischemic heart disease (IHD) and peripheral arterial disease, while renal dysfunction leads to a wider impaired, including hypertension, cerebrovascular disease, chronic kidney disease and renal failure. Additionally, SUA and renal status mediate the pathological process of cardiovascular-kidney-metabolic syndrome caused by its risk factors. More importantly, we clarified the therapeutic role of lesinurad in IHD. Besides, we identified SUA as a key biologic marker associated with social determinants of health and proposed: lower social status will cause high SUA levels and further result in cardiovascular disease. • Elevated serum uric acid (SUA) is the culprit behind ischemic heart disease and peripheral arterial disease. • Renal dysfunction leads to a wider impaired, including hypertension, cerebrovascular disease, chronic kidney disease and renal failure. • SUA and renal status mediate the pathological process of cardiovascular-kidney-metabolic syndrome caused by its risk factors. • Lesinurad is a potential therapy for ischemic heart disease. • Lower social status will cause high SUA levels and further result in cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: